A STUDY TO EVALUATE THE EFFICACY OF CJH1 (CLR4001) IN PARKINSON’S DISEASE

Overview

The purpose of this study is to assess the ability of CJH1 to increase the sensitivity of dopamine receptors and thereby reduce symptoms of Parkinson's Disease.

Full Title of Study: “A STUDY TO EVALUATE THE EFFICACY OF CJH1 [CLR4001] IN THE TREATMENT OF PARKINSON’S DISEASE”

Study Type

  • Study Type: Interventional
  • Study Design
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: September 2013

Interventions

  • Drug: CJH1 (CLR4001)

Arms, Groups and Cohorts

  • Experimental: Treatment with CJH1

Clinical Trial Outcome Measures

Primary Measures

  • Reduced signs and symptoms of Parkinson’s disease
    • Time Frame: 8 weeks
    • Reduced signs and symptoms of Parkinson’s disease

Participating in This Clinical Trial

Inclusion Criteria

  • Patient's with Parkinson's disease

Exclusion Criteria

  • Contraindications to study medication

Gender Eligibility: All

Minimum Age: 40 Years

Maximum Age: 85 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Alexandra Marine and General Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Craig Hudson MD, Psychiatrist – Alexandra Marine and General Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.